[1. Pattali R, Mou Y, Li XJ. AAV9 Vector: a Novel modality in gene therapy for spinal muscular atrophy. Gene Ther 2019; 26(7–8): 287–295.]Search in Google Scholar
[2. Kariyawasam D, Carey KA, Jones KJ, Farrar MA. New and developing therapies in spinal muscular atrophy. Paediatr Respir Rev 2018; 28: 3–10.]Search in Google Scholar
[3. Mendell JR, Al-Zaidy S, Shell R et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med 2017; 377(18): 1713–1722.]Search in Google Scholar
[4. Chen TH. New and developing therapies in spinal muscular atrophy: from genotype to phenotype to treatment and where do we stand? Int J Mol Sci 2020; 21(9): 3297.]Search in Google Scholar
[5. Dangouloff T, Servais L. Clinical evidence supporting early treatment of patients with spinal muscular atrophy: current perspectives. Ther Clin Risk Manag 2019; 15: 1153–1161.]Search in Google Scholar
[6. Al-Zaidy SA, Mendell JR. From clinical trials to clinical practice: practical considerations for gene replacement therapy in SMA type 1. Pediatr Neurol 2019; 100: 3–11.]Search in Google Scholar
[7. Messina S, Sframeli M. New treatments in spinal muscular atrophy: positive results and new challenges. J Clin Med 2020; 9(7): 2222.]Search in Google Scholar
[8. Hoy SM. Onasemnogene abeparvovec: first global approval. Drugs 2019; 79(11): 1255–1262.]Search in Google Scholar
[9. Kirschner J, Butoianu N, Goemans N et al. European ad-hoc consensus statement on gene replacement therapy for spinal muscular atrophy. Eur J Paediatr Neurol 2020; 28: 38–43.]Search in Google Scholar
[10. Rao VK, Kapp D, Schroth M. Gene therapy for spinal muscular atrophy: an emerging treatment option for a devastating disease. J Manag Care Spec Pharm 2018; 24(supl 12-a): S3–S16.]Search in Google Scholar
[11. Hensel N, Kubinski S, Claus P. The need for SMN-independent treatments of spinal muscular atrophy (SMA) to complement SMN-enhancing drugs. Front Neurol 2020; 11: 45.]Search in Google Scholar
[12. Zakharova M. Modern approaches in gene therapy of motor neuron diseases. Med Res Rev 2020 [online ahead of print].]Search in Google Scholar
[13. Lugin ML, Lee RT, Kwon YJ. Synthetically engineered adeno-associated virus for efficient, safe, and versatile gene therapy applications. ACS Nano 2020 [online ahead of print].]Search in Google Scholar
[14. Malone DC, Dean R, Arjunji R et al. Cost-effectiveness analysis of using onasemnogene abeparvocec (AVXS-101) in spinal muscular atrophy type 1 patients. J Mark Access Health Policy 2019; 7(1): 1601484.]Search in Google Scholar
[15. Nidetz NF, McGee MC, Tse LV et al. Adeno-associated viral vector--mediated immune responses: understanding barriers to gene delivery. Pharmacol Ther 2020; 207: 107453.]Search in Google Scholar
[16. Waldrop MA, Kolb SJ. Current treatment options in neurology-SMA therapeutics. Curr Treat Options Neurol 2019; 21(6): 25.]Search in Google Scholar
[17. Kariyawasam D, Carey KA, Jones KJ, Farrar MA. New and developing therapies in spinal muscular atrophy. Paediatr Respir Rev 2018; 28: 3–10.]Search in Google Scholar
[18. Yeo CJJ, Darras BT. Overturning the paradigm of spinal muscular atrophy as just a motor neuron disease. Pediatr Neurol 2020; 109: 12–19.]Search in Google Scholar
[19. Waldrop MA, Karingada C, Storey MA et al. Gene therapy for spinal muscular atrophy: safety and early outcomes. Pediatrics 2020; 146(3): e20200729.]Search in Google Scholar
[20. Al-Zaidy SA, Kolb SJ, Lowes L et al. AVXS-101 (onasemnogene abeparvovec) for SMA1: comparative study with a prospective natural history cohort. J Neuromuscul Dis 2019; 6(3): 307–317.]Search in Google Scholar
[21. Al-Zaidy S, Pickard AS, Kotha K et al. Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy. Pediatr Pulmonol 2019; 54(2): 179–185.]Search in Google Scholar
[22. Lowes LP, Alfano LN, Arnold WD et al. Impact of age and motor function in a phase 1/2A study of infants with SMA type 1 receiving single-dose gene replacement therapy. Pediatr Neurol 2019; 98: 39–45.]Search in Google Scholar
[23. Harada Y, Rao VK, Arya K et al. Combination molecular therapies for type 1 spinal muscular atrophy. Muscle Nerve 2020; 62(4): 550–554.]Search in Google Scholar
[24. Paul GR, Gushue C, Kotha K, Shell R. The respiratory impact of novel therapies for spinal muscular atrophy. Pediatr Pulmonol 2020 [online ahead of print].]Search in Google Scholar
[25. Dabbous O, Maru B, Jansen JP et al. Survival, motor function, and motor milestones: comparison of AVXS-101 relative to nusinersen for the treatment of infants with spinal muscular atrophy type 1. Adv Ther 2019; 36(5): 1164–1176.]Search in Google Scholar
[26. Waldrop MA, Elsheikh BH. Spinal muscular atrophy in the treatment era. Neurol Clin 2020; 38(3): 505–518.]Search in Google Scholar
[27. Rashnonejad A, Amini Chermahini G, Gündüz C et al. Fetal gene therapy using a single injection of recombinant AAV9 rescued SMA phenotype in mice. Mol Ther 2019; 27(12): 2123–2133.]Search in Google Scholar
[28. Hinderer C, Katz N, Buza EL et al. Severe toxicity in nonhuman primates and piglets following high-dose intravenous administration of an adeno-associated virus vector expressing human SMN. Hum Gene Ther 2018; 29(3): 285–298.]Search in Google Scholar
[29. Keeler AM, Flotte TR. Recombinant adeno-associated virus gene therapy in light of Luxturna (and Zolgensma and Glybera): where are we, and how did we get here? Annu Rev Virol 2019; 6(1): 601–621.]Search in Google Scholar
[30. Kariyawasam DST, Russell JS, Wiley V, Alexander IE, Farrar MA. The implementation of newborn screening for spinal muscular atrophy: the Australian experience. Genet Med 2020; 22(3): 557–565.]Search in Google Scholar
, 